About this episode

The episode features an interview with David Elsley discussing Cardiol Therapeutics' approach to treating inflammation in heart disease.

This interview is disseminated on behalf of Cardiol Therapeutics Inc. In this episode of Stocks to Watch, we sit down with David Elsley, President and CEO of Cardiol Therapeutics (NASDAQ: CRDL | TSX: CRDL), to discuss the company's late-stage clinical development program targeting inflammation-driven heart conditions, including recurrent pericarditis and acute myocarditis. Learn more: https://www.cardiolrx.com Watch the full YouTube interview here: https://youtu.be/NXkzgfWHQnA And follow us to stay updated: https://www.youtube.com/GlobalOneMedia

People in this episode

Host: Global One Media Pte. Ltd.

Guest: David Elsley

Topics covered

• heart disease
• inflammation
• clinical development
• recurrent pericarditis
• acute myocarditis

Keywords

• Cardiol Therapeutics
• CRDL
• heart disease
• inflammation
• clinical trials
• myocarditis
• pericarditis

Mentioned in this episode

Organizations: Cardiol Therapeutics Inc., NASDAQ, TSX

More episodes of Stocks To Watch

• Episode 823: Aftermath Silver ($AAG | $AAGFF) CEO on Berenguela Project Drill Results and Next Steps · May 29, 2026 · 9 min
• Episode 822: Conexeu Sciences ($CNXU): The Future of Regenerative Aesthetics · May 27, 2026 · 25 min
• Episode 821: The FUTR Corporation CEO Discusses the Economic Opportunity Behind AI Banking and Consumer Data · May 21, 2026 · 17 min
• Episode 820: Don Durrett Shares His Checklist for Picking Mining Stocks · May 20, 2026 · 27 min
• Episode 818: Planet Ventures Inc. ($PXI | $PNXPF): Breaking Barriers to Emerging Private Space Opportunities · May 19, 2026 · 11 min
• Episode 817: North American Niobium ($NIOB | $NIOMF) Expands Pegmatite System at the Seigneurie Project · May 19, 2026 · 17 min

Explore listener stats, chart rankings, contacts and more on the Stocks To Watch podcast page.